JOP20200290A1 - تركيبة RUR20kD-IL-2 الانتقائية لمحفز TREG وتركيبات ذات صلة - Google Patents
تركيبة RUR20kD-IL-2 الانتقائية لمحفز TREG وتركيبات ذات صلةInfo
- Publication number
- JOP20200290A1 JOP20200290A1 JOP/2020/0290A JOP20200290A JOP20200290A1 JO P20200290 A1 JOP20200290 A1 JO P20200290A1 JO P20200290 A JOP20200290 A JO P20200290A JO P20200290 A1 JOP20200290 A1 JO P20200290A1
- Authority
- JO
- Jordan
- Prior art keywords
- rur20kd
- compositions
- related compositions
- treg stimulator
- selective treg
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 210000003162 effector t lymphocyte Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000003289 regulatory T cell Anatomy 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
يتعلق الكشف الحالي بتوفير تركيبات انتقائية لمحفز Treg، بما في ذلك RUR20kD-IL-2 وتركيبات ذات صلة، وطرق لاستخدام هذه التركيبات، على سبيل المثال، لعلاج أمراض المناعة الذاتية، و/أو الحالات الأخرى التي تستجيب للعلاج الفعال لتوفير زيادة انتقائية في أعداد ونشاط الخلايا التائية المنظِّمة مقارنةً بالخلايا التائية المستفعلة.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862674244P | 2018-05-21 | 2018-05-21 | |
PCT/US2019/033100 WO2019226538A1 (en) | 2018-05-21 | 2019-05-20 | SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20200290A1 true JOP20200290A1 (ar) | 2020-11-15 |
Family
ID=67002369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2020/0290A JOP20200290A1 (ar) | 2018-05-21 | 2019-05-20 | تركيبة RUR20kD-IL-2 الانتقائية لمحفز TREG وتركيبات ذات صلة |
Country Status (20)
Country | Link |
---|---|
US (1) | US20210205413A1 (ar) |
EP (1) | EP3796940A1 (ar) |
JP (2) | JP7235772B2 (ar) |
KR (1) | KR20210002577A (ar) |
CN (1) | CN112399859A (ar) |
AU (2) | AU2019274409B2 (ar) |
BR (1) | BR112020021564A2 (ar) |
CA (1) | CA3100204A1 (ar) |
CL (1) | CL2020003008A1 (ar) |
CO (1) | CO2020014510A2 (ar) |
CR (1) | CR20200546A (ar) |
DO (1) | DOP2020000212A (ar) |
EA (1) | EA202092489A1 (ar) |
EC (1) | ECSP20074392A (ar) |
IL (1) | IL278528B1 (ar) |
JO (1) | JOP20200290A1 (ar) |
PE (1) | PE20211307A1 (ar) |
PH (1) | PH12020551976A1 (ar) |
SG (1) | SG11202011242SA (ar) |
WO (1) | WO2019226538A1 (ar) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2021206449A1 (en) | 2020-01-10 | 2022-07-21 | Bright Peak Therapeutics Ag | Modified IL-2 polypeptides and uses thereof |
CN113121670B (zh) * | 2020-01-15 | 2022-11-22 | 天津键凯科技有限公司 | 二取代peg化白细胞介素2及其制备方法、应用 |
EP4092048A4 (en) * | 2020-01-15 | 2023-07-26 | Jenkem Technology Co. Ltd. (Tianjin) | METHOD FOR PREPARING PEGYLATED BIOMOLECULES HAVING CONTROLLABLE BINDING SITES |
US20230272001A1 (en) * | 2020-05-22 | 2023-08-31 | Merck Sharp & Dohme Llc | Novel processes for preparing conjugates of the il-2 protein |
TW202228784A (zh) | 2020-09-23 | 2022-08-01 | 奧地利商艾柏力維亞生技有限公司 | 用以於一患者中螯合非預期的抗peg抗體的化合物 |
WO2022109477A1 (en) * | 2020-11-23 | 2022-05-27 | University Of Florida Research Foundation, Incorporated | Use of insulin-like growth factors with gamma-chain cytokines to induce homeostatic proliferation of lymphocytes |
CA3239501A1 (en) | 2021-12-14 | 2023-06-22 | Ali ASHRAFZADEH | Dosing regimens for selective treg stimulator rur20kd-il-2 and related compositions |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4401756A (en) | 1981-04-14 | 1983-08-30 | Immunex Corporation | Process for preparing human interleukin 2 |
US4569790A (en) | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
US5116943A (en) | 1985-01-18 | 1992-05-26 | Cetus Corporation | Oxidation-resistant muteins of Il-2 and other protein |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US5153310A (en) | 1989-02-28 | 1992-10-06 | Du Pont Merck Pharmaceutical Company | Il-2 analogs containing n-linked glycosylation sites |
US5635597A (en) | 1994-05-27 | 1997-06-03 | Affymax Technologies, N.V. | Peptides that bind IL-2 receptors |
US6168785B1 (en) | 1998-07-16 | 2001-01-02 | Institut Pasteur | Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents |
FR2826365B1 (fr) | 2001-06-20 | 2003-09-26 | Oreal | Compositions cosmetiques photoprotectrices contenant des derives amides, sulfonamides ou carbamates aromatiques d'acrylonitrile et nouveaux derives amides, sulfonamides ou carbamates d'acrylonitrile |
ES2725808T3 (es) | 2003-05-23 | 2019-09-27 | Nektar Therapeutics | Derivados de PEG que contienen dos cadenas de PEG |
US7569215B2 (en) | 2003-07-18 | 2009-08-04 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
US7567215B1 (en) | 2007-10-23 | 2009-07-28 | The United States Of America As Represented By The Secretary Of The Navy | Portable and inflatable antenna device |
KR102591732B1 (ko) * | 2010-11-12 | 2023-10-19 | 넥타르 테라퓨틱스 | Il-2 부분 및 중합체의 접합체 |
WO2012123381A1 (en) * | 2011-03-11 | 2012-09-20 | Assistance Publique - Hôpitaux De Paris | Use of low dose il-2 for treating autoimmune - related or inflammatory disorders |
JP6911044B2 (ja) * | 2016-03-16 | 2021-07-28 | シェ、ヤンホイXie Yanhui | 呼吸器系疾患の治療のためのグルココルチコイドとポリエチレングリコール修飾インターロイキン2の組合せ |
-
2019
- 2019-05-20 EA EA202092489A patent/EA202092489A1/ru unknown
- 2019-05-20 AU AU2019274409A patent/AU2019274409B2/en active Active
- 2019-05-20 PE PE2020001854A patent/PE20211307A1/es unknown
- 2019-05-20 IL IL278528A patent/IL278528B1/en unknown
- 2019-05-20 WO PCT/US2019/033100 patent/WO2019226538A1/en active Application Filing
- 2019-05-20 KR KR1020207033346A patent/KR20210002577A/ko active IP Right Grant
- 2019-05-20 US US17/056,050 patent/US20210205413A1/en active Pending
- 2019-05-20 CR CR20200546A patent/CR20200546A/es unknown
- 2019-05-20 EP EP19732788.5A patent/EP3796940A1/en active Pending
- 2019-05-20 JP JP2020564540A patent/JP7235772B2/ja active Active
- 2019-05-20 SG SG11202011242SA patent/SG11202011242SA/en unknown
- 2019-05-20 CA CA3100204A patent/CA3100204A1/en active Pending
- 2019-05-20 BR BR112020021564-3A patent/BR112020021564A2/pt unknown
- 2019-05-20 CN CN201980034052.1A patent/CN112399859A/zh active Pending
- 2019-05-20 JO JOP/2020/0290A patent/JOP20200290A1/ar unknown
-
2020
- 2020-11-18 PH PH12020551976A patent/PH12020551976A1/en unknown
- 2020-11-19 CL CL2020003008A patent/CL2020003008A1/es unknown
- 2020-11-19 DO DO2020000212A patent/DOP2020000212A/es unknown
- 2020-11-20 EC ECSENADI202074392A patent/ECSP20074392A/es unknown
- 2020-11-23 CO CONC2020/0014510A patent/CO2020014510A2/es unknown
-
2022
- 2022-10-06 AU AU2022246440A patent/AU2022246440A1/en active Pending
- 2022-12-23 JP JP2022206250A patent/JP2023052053A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210205413A1 (en) | 2021-07-08 |
AU2019274409B2 (en) | 2022-07-14 |
CA3100204A1 (en) | 2019-11-28 |
ECSP20074392A (es) | 2021-03-31 |
EP3796940A1 (en) | 2021-03-31 |
JP7235772B2 (ja) | 2023-03-08 |
PE20211307A1 (es) | 2021-07-20 |
AU2019274409A1 (en) | 2020-11-12 |
JP2021523922A (ja) | 2021-09-09 |
WO2019226538A1 (en) | 2019-11-28 |
IL278528B1 (en) | 2024-06-01 |
CR20200546A (es) | 2021-05-18 |
PH12020551976A1 (en) | 2021-09-13 |
BR112020021564A2 (pt) | 2021-03-02 |
CO2020014510A2 (es) | 2021-03-08 |
DOP2020000212A (es) | 2021-03-15 |
IL278528A (ar) | 2021-01-31 |
JP2023052053A (ja) | 2023-04-11 |
AU2022246440A1 (en) | 2022-11-03 |
EA202092489A1 (ru) | 2021-03-16 |
CN112399859A (zh) | 2021-02-23 |
CL2020003008A1 (es) | 2021-07-30 |
SG11202011242SA (en) | 2020-12-30 |
KR20210002577A (ko) | 2021-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020551976A1 (en) | SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS | |
WO2020086726A3 (en) | Nerve stimulation for treating migraine and other headache conditions | |
MX2020008906A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso de estos. | |
PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
MX2022011546A (es) | Composiciones y metodos para el agotamiento de celulas cd137+. | |
WO2019006005A3 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA | |
MX2018008624A (es) | Metodo para tratar glomerulopatia c3. | |
EA201791518A1 (ru) | Способы лечения заболеваний сетчатки | |
MX2019005402A (es) | Terapias de combinacion del inhibidor de arginasa. | |
MX2020011817A (es) | Metodos para tratar el linfoma. | |
NZ741785A (en) | 3-cyano-1h-1,2,4-triazol-1-yl compounds and uses thereof for the treatment of hiv | |
MX2021010173A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso. | |
WO2019157495A3 (en) | Methods for preventing and/or treating bone loss conditions by modulating irisin | |
MX2020011254A (es) | Celulas t car anti-bcma para agotamiento de celulas de plasma. | |
MX2019013862A (es) | Terapia de combinacion. | |
MX2022006073A (es) | Metodos para utilizar anticuerpos anti-trem2. | |
PH12017500392A1 (en) | Medical treatments based on anamorelin | |
MX2021013354A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
MX2021014905A (es) | Células seguras e invisibles para el sistema inmunitario. | |
MX2018008903A (es) | COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA. | |
MX2020011263A (es) | Metodos y composiciones de agotamiento de celulas t citotoxicas. | |
MX2020013621A (es) | Composiciones y metodos de tratamiento de vih. | |
MX2021002982A (es) | Composiciones y metodos para tratar retinitis pigmentosa. | |
WO2019040105A3 (en) | COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES | |
MX2022006883A (es) | Uso de isatuximab para el tratamiento del mieloma multiple recidivante y/o refractario. |